Barclays has upgraded shares of Merck & Co., Inc. (NYSE: MRK) to a “strong-buy” rating, according to a research report published on Thursday. This upgrade reflects growing confidence in the company’s financial performance and future prospects.
Several other financial analysts have also recently provided their assessments of Merck’s stock. Cantor Fitzgerald raised its target price from $116.00 to $120.00, maintaining a “neutral” rating. Similarly, Citigroup increased its price objective from $115.00 to $120.00 while keeping a “neutral” outlook. In contrast, Zacks Research downgraded Merck from a “hold” rating to a “strong sell” rating earlier this month.
As of now, one analyst has rated Merck’s stock as a “strong buy,” nine have given it a “buy” rating, six have assigned a “hold” rating, and one has issued a “sell” rating. According to data from MarketBeat.com, the consensus rating for Merck is “moderate buy,” with an average target price of $124.80.
Latest Earnings Report Shows Strong Performance
Merck’s most recent quarterly earnings report, released on February 3, 2024, demonstrated solid financial results. The company reported earnings per share (EPS) of $2.04, surpassing analysts’ expectations of $2.01 by $0.03. Revenue for the quarter reached $16.40 billion, exceeding the anticipated $16.19 billion. This performance marks a 5.0% increase in quarterly revenue compared to the same period last year, during which Merck posted an EPS of $1.72.
Looking ahead, Merck has set its fiscal year 2026 guidance at $5.000 to $5.150 EPS. Analysts project that the company will achieve an EPS of $9.01 for the current fiscal year.
Dividend Announcement and Insider Trading Activity
In related news, Merck announced a quarterly dividend of $0.85 per share, scheduled for payment on April 7, 2024. Shareholders of record on March 16, 2024 will receive this dividend, which translates to an annualized dividend of $3.40 and a yield of 2.8%. The company’s dividend payout ratio currently stands at 46.70%.
Recent insider activity has seen Jennifer Zachary, Executive Vice President, sell 121,573 shares of Merck at an average price of $119.15, totaling approximately $14.5 million. Following this sale, she retains 68,916 shares, valued at about $8.2 million. Additionally, another executive, Richard R. Deluca, sold 37,685 shares at an average price of $120.92, amounting to roughly $4.6 million. In total, insiders have sold 320,176 shares valued at approximately $38.3 million in the last ninety days, with insiders currently holding 0.13% of the stock.
Institutional investors have also been active in adjusting their positions in Merck. Several firms, including Kingdom Financial Group LLC and Darwin Wealth Management LLC, have recently acquired stakes in the company, signaling continued interest from larger investment entities. Currently, institutional investors own 76.07% of Merck’s stock.
Merck & Co., Inc., established in the late 19th century, is a global biopharmaceutical company focused on developing a range of prescription medicines, vaccines, and biologic therapies. The company’s portfolio includes well-known products such as the cancer immunotherapy Keytruda and the HPV vaccine Gardasil, highlighting its commitment to addressing critical health challenges.
